THE SML

GUIDEBOOK
Developed for professional Ophthalmic Practitioners

THE MAGNIFIER IN THE EYE

Learn more at
www.maculalens.com
Chapter Overview

1. Introduction
   a. AMD worldwide
   b. SML history
   c. Multicentric study
   d. How do I start?

2. The SML
   a. Characteristics
      I. Material
      II. Design
   b. Functionality – Mode of Action
   c. Advantages of the SML

3. The SML Experience
   a. Pre-Operative
      I. Indications and contraindications
      II. Examination – Setting up a predictable outcome – level expectations
      III. The SML Advisor
   b. Implantation
      I. Step-by-Step Guide
      II. Possible complications and recommendations
   c. Post-Operative
      I. Patient training
Just how common is AMD?

AMD is the **most common cause of irreversible blindness** in both developed and developing countries, particularly in people older than 60 years.

AMD is more common in women than men and people of Caucasian and Chinese ethnicity are more likely to be affected by the disease.

Approximately **30 million** humans are affected by the disease, around 90% of these have the **dry**, or non-exudative form of AMD.

Two thirds of patients with advanced AMD and a visual acuity of 0.3 or less are **pseudophakic** - these patients can benefit from the **SML**.

### Treatment of AMD

There have been significant advances in the treatment of exudative (**wet**) AMD with the introduction of anti-angiogenesis therapy, and patients now have effective treatment options that can prevent blindness and, in many cases, restore their vision.

**HOWEVER,**

currently there is **no medication available for dry AMD** and treatment possibilities are limited to low vision rehabilitation devices (low vision aids and low vision intraocular implants).

The **SML technology** was developed to enhance the quality of life of pseudophacic patients with **advanced dry AMD**. It can also be helpful for patients with other macular diseases, e.g. myopic maculopathy, diabetic retinopathy or certain hereditary retinal diseases.

---

**The most common causes of blindness in developed countries**

- **Diabetic Retinopathy**
- **Glaucoma**
- **AMD**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic Retinopathy</td>
<td>3 million</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>10%</td>
</tr>
<tr>
<td>AMD</td>
<td>90%</td>
</tr>
</tbody>
</table>

**Dry AMD, 27 million**

**Wet AMD, 3 million**
The SML is a joint innovation of Prof. Gábor Scharioth and Medicontur Medical Engineering, a medical device company with 30 years of focused experience with intraocular implants.

The SML was first implanted in 2013 and there have been over 500 commercial implantations worldwide since.

During my ophthalmological practice macular diseases have always been my special concern, especially Age-related Macular Degeneration. I had to find again and again that patients evaluate treatment outcomes differently from us doctors. While a patient maintains his ability to focus and orientate himself, he is usually not able to read anymore. These observations finally led to the development of our Macula Lens in cooperation with the Hungarian company Medicontur Medical Engineering. Prof. Gábor B. Scharioth

Medicontur Medical Engineering is an independent European company in existence since 1988. With more than 4 million intraocular implants produced and sold across 60 countries, we have been at the forefront of developing innovative solutions in material, design and optics. The SML project gives AMD patients the chance to regain their lost abilities and to improve their quality of life. This is something that we, together with Prof. Gabor Scharioth, are very proud of. Alexandra Kontur, MD, PhD Scientific Director
Clinical Studies confirmed the efficacy and safety of the SML.

Quick facts:
- 8 countries
- 9 centers
- 106 eyes implanted in total

Conclusion of the clinical studies:
- **PREDICTABILITY** = Strong correlation between preoperative CNVA +6.0D at 15 cm and postoperative NVA at 15 cm
- Preoperative testing:
  - Allows to predict postoperative results
  - Enables setting realistic expectations with patients
  - Patients were satisfied or highly satisfied
- Improvement with time and training: NVA: D1 < D7 < M1: After 1 month near visual acuity was stable (unless the maculopathy worsened)

**TRAINING**
- Postsurgical training of patients is of utmost importance
- Significantly improves outcome after surgery

Please note: If indications are set properly & patients are trained appropriately after surgery, results are good or excellent.

HOW DO I START?

To be successful with the SML there are some preconditions to guarantee an adequate setup:

? you work at a clinic or an outpatient surgery center
? you have experience with macular degeneration & low vision patients
? you are prepared for diagnosing low vision patients (available personnel & equipment)
? you have a trained doctor or optician to take care of low vision patients.
? you are a cataract surgeon
? you are a retinal specialist or you have a retinal specialist in your team
? you have OCT (for macular imaging) at the clinic
? you have a doctor and/or an optician who will be dedicated for pre- and post-operative care and training of implanted patients or you cooperate or have an agreement with an organization taking care of low-vision patients.

Our first SML Patient
What does it take to get happy patients?

1. Precise patient selection and indication (supported by the Medicontur Scientific Team + tools),
2. Alignment of expectations and reality
3. Postsurgical patient training!

SURGEONS ARE SATISFIED WITH THE OUTCOMES AFTER IMPLANTATION OF PATIENTS WITH SML

“"I have found SML as a simple, safe and effective option to enhance the reading vision in patients with-age related macular degeneration."”

Sathish Srinivasan FRCSEd, FRCOphth, FACS
(Ayrshire Eye clinic, Ayr, Scotland, UK)

“"SML - a new hope for patients with AMD, return to active life without stigmatization and for a reasonable price."”

Prof. MUDr. Pavel Rozšíval, CSc
(Teaching Hospital, Charles University, Hradec Kralove, Czech Republic)

“"Patient selection is paramount. In case of our meticulously selected macular patients the SML provided a good reading visual acuity. Patients were enthusiastic about the results - so was I."”

Prof. Zoltan Z. Nagy, MD, med.habil, DSC
(Semmelweis University, Budapest, Hungary)

“"The SML is an important progress for AMD patients, to manage their daily routine."”

Anneliese Riehl, MD
(nordBLICK Augenklinik Bellevue, Kiel, Germany)

“"An opportunity to change."”

Gustav Muus, Managing Director at the Eye Hospital Denmark
SML Material

- The SML is made of a copolymer of Hydrophilic and Hydrophobic Acrylic with 25% water content.
- It comes with a UV absorber and is also available with an additional blue light filter.

SML Design

- The SML is an intraocular sulcus lens that has a **bifocal design** with a central optical zone of 1.5mm in diameter.
- This optical zone provides a +10 diopter addition for patients.
- The peripheral zone is neutral, leaving the patient’s distance vision and visual field unaffected.
- The special convex-concave optic maintains distance between the implants, preventing IOLs from touching each other.
- Due to its round polished edges the IOL has no chafing effect.
- The main square design prevents iris capture.
- The haptics’ non-torque design ensures rotational stability.

SML is SAFE

The SML design was based on the **Medicontur Add-On Platform design** which has gained industry-wide attention for its excellent stability and ergonomic fit within the ciliary sulcus. The Add-On platform has been proven clinically (over 5,000 implantations) and in an in vitro study to be safe (Reiter et al. Assessment of a New Hydrophilic Acrylic Supplementary IOL for Sulcus Fixation in Pseudophakic Cadaver Eyes. Eye 2017; 31: 802-809)
Using the Near Triad Reflex: miosis – accommodation – convergence

Due to the effect of near vision miosis, the central optical portion that provides the magnified image will dominate when the patient focuses on near objects only, but will not influence far vision significantly when the patient focuses on distant objects through a dilated pupil.

**Near vision:**
The pupil is constricted (near vision miosis) and light rays pass through the central region of the SML, providing a magnified image on the macula (Figure 1). Due to the high dioptric power of the central region, sharp vision is achieved at a distance of about 15 cm.

**Distance vision:**
The pupil is dilated when focusing on a distant object and thus light rays passing through the peripheral region of the SML will dominate over those passing through the central region (dashed lines) (Figure 2).
The SML works through magnification (2.2 times)
The dark spots (scotomas) covering the text represent damaged macular areas. The SML magnifies the text approximately 2 times but the size of the dark spots remains the same because the SML does not magnify the damaged parts of the macula. Thus, the SML enables patients with dry AMD to read the text.

Enlargement by Zooming:

Advantages of the SML

- Easy and safe surgery
- Small incision (2.2-2.4mm)
- No visual field reduction
- Unaffected distance vision
- Independent from lens status
- Quick adaptation
- Reversible
- Affordable

All examinations needed for a patient’s regular follow-up after implantation with the SML (retina/macula visualization, OCT etc.) are unaffected

All treatments, if needed, can be performed without limitations:

- Intravitreal injections in case of exacerbation of maculopathy
- Laser treatment of retina
- YAG capsulotomy
How to choose a suitable patient?
KEY: MOTIVATION & SETTING REALISTIC EXPECTATIONS AND POST-SURGICAL TRAINING WITH THE PATIENT

Indications

The SML is recommended for motivated patients:
• With dry AMD and near vision difficulties
• With other stable retinal conditions (diabetic retinopathy, myopic retinopathy, some hereditary retinal diseases proven by OCT) – Please contact us for further information.
• Who are pseudophakic or candidates for cataract surgery
• Who show sufficient near vision improvement on near vision tests performed with +2.5D at 40 cm and with +6.0D at 15 cm
• BCDVA
  • equal or less than 0.32 decimal ETDRS (equivalent to 6/18)
  • equal or more than 0.1 (decimal ETDRS charts; equivalent to 6/60)
  * Please note that the patient may still benefit from the SML if outside of the above range. Please contact Medicontur to find out more.

Points to remember:
• The implanted eye should be the better seeing one
• Interval between OCT & surgery should not exceed 10 days
• Interval between cataract surgery and the SML implantation should be at least one month
• Simultaneous surgery (cataract extraction and Add-on lens implantation as a dual procedure) is possible, but not currently recommended by Medicontur
• Clear lens extraction and intracapsular IOL & SML implantation in one session is possible
• Each eye should be tested monocularly for distance (UCDVA & BCDVA) and near visual acuity
Examination and setting up a predictable outcome – level expectations

HOW TO SELECT A SUITABLE PATIENT?

- Preoperative CNVA needs to be examined as follows:
- Patients read at a distance of 40 cm with an addition of +2.5D placed over their distance prescription eyeglasses (examination A) and then at a distance of 15 cm with an addition of +6.0D placed over their distance prescription eyeglasses (examination B).
- The patient is a good candidate for the SML implantation if there is 3 or more lines of improvement between examination A and B.
- The patient may still benefit from SML implantation in case of 1 or 2 lines of improvement (please consult Medicontur or your local distributor).

IMPORTANT: based on these near vision tests, we can estimate the likely near visual acuity of the patients after implantation of the SML. It is important to communicate this with the patients and to set realistic expectations for them.

IMPORTANT:
- SML DOES NOT cure maculopathy.
- SML is a magnifier. It is like a low vision aid inside the eye.
- Exacerbation of maculopathy might occur any time after the implantation of the SML.
- The SML does not affect /limit any diagnostic or treatment procedures of exacerbated maculopathy.

Contraindications

- Active neovascular AMD/maculopathy
- Active iris neovascularisation
- Zonulopathy
- Subluxation of the primary IOL
- Shallow pseudophakic ACD (< 2.8 mm; from endothel)
- Narrow angle, i.e. < Schaefer grade 2
- Pigment dispersion syndrome
- Uveitis
- Pupillary abnormalities (photopic pupil less than 2.5 mm)
- Aphakia
- Progressive glaucoma
- Corneal diseases involving central cornea
The SML Advisor

The SML ADVISOR is your personal consultant and it helps you select the optimal patients who will BENEFIT from the SML.

- Easy to use
- Time saving (5 min)

Available at www.smladvisor.com

In 4 easy steps, the tool lets you:

- **Determine if a patient is suitable** for SML implantation
- Determine the **more suitable eye** for implantation as well as the optimal SML type (clear/yellow)
- **Estimate** the extent of visual acuity improvement
- Generate a **pdf and/or printout** that includes detailed patient data and the results of the evaluation, which you can then add to the **patient’s records**.
- Generate, save, print or send the order form right away if the patient was evaluated as suitable for the implantation.

**CAUTION:**
Even the best online tools cannot substitute accurate measurements and the opinion of a specialist ophthalmologist.

If you have any further questions please contact us at scientific@medicontur.hu
THE SML EXPERIENCE – IMPLANTATION

Step-by-Step Guide

• Implantation in the ciliary sulcus is performed following cataract surgery but implantations may be performed simultaneously if necessary
• Monocular implantation in the better-seeing eye
• Easy implantation using a standard IOL injector through a 2.2 mm incision
• No extensive training is required – minimal learning curve

Possible complications and recommendations

Complications are not common but may occur

• WET AMD development: So far there is no clear evidence that intravitreal injection of anti-VGEF may prevent decompensation/development of wet AMD after the implantation of SML under dry & stable AMD conditions. For this reason the preventive use of anti-VGEF is currently not recommended by Medicontur.
• SD-OCT macula is recommended to be performed before surgery, ideally no more than 10 days before surgery to avoid hidden / developing wet AMD.
• Inflammatory reaction in the anterior chamber. Anti-inflammatory drugs like corticosteroids (for up to 3 weeks after surgery) and NSAIDs (for up to 2 months after surgery) are recommended.
• Far vision disturbances (halos, glares). We recommend sunglasses and if these are not effective, we recommend so-called Neutral Density Filter glasses. Pilocarpine can also be considered if sunglasses are not effective in reducing these symptoms.
TRAINING AFTER SURGERY IS OF UTMOSt IMPORTANCE
Patients need to practice performing near vision reading tasks without the use of magnifying aids. This should be performed 2-3 times a day for at least 20 minutes at a time during the first 4-8 weeks following SML implantation.
The eye without the SML implantation may need to be covered during the first few days after SML implantation when reading.
The reading material needs to be held at approximately 15–18 cm from the patient’s eye. Good lighting conditions and high contrast reading materials are recommended. A dedicated and experienced low vision expert is necessary for achieving optimal results after surgery.
The adaptation is quick: it usually takes 2-5 weeks after surgery.

DO NOT FORGET:
READING DISTANCE IS APPROXIMATELY 15–18 cm (6”) FROM THE PATIENT’S EYE